Skip to main content

Table 1 Patient demographics, baseline disease, and clinical characteristics

From: Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk

 

Standard cytogenetic riska

High cytogenetic riska,b

Characteristic

D-Vd (n = 141)

Vd (n = 140)

D-Vd (n = 40)

Vd (n = 35)

Age, years

 Median (range)

64 (40–88)

64 (33–85)

63 (37–79)

59 (37–81)

 ≥ 75 years, n (%)

9 (6)

20 (14)

4 (10)

5 (14)

Sex, n (%)

 Male

79 (56)

89 (64)

22 (55)

18 (51)

Race, n (%)

 White

123 (87)

123 (88)

33 (83)

31 (89)

 Black or African American

9 (6)

2 (1)

1 (3)

1 (3)

 Asian

8 (6)

8 (6)

4 (10)

2 (6)

 Native Hawaiian or other Pacific Islander

1 (1)

0

0

0

 Other

0

1 (1)

0

0

 Unknown/not reported

0

6 (4)

2 (5)

1 (3)

ISS stage, n (%)c

 I

48 (34)

55 (39)

22 (55)

14 (40)

 II

57 (40)

56 (40)

11 (28)

16 (46)

 III

36 (26)

29 (21)

7 (18)

5 (14)

ECOG performance status score, n (%)

 0

54 (38)

64 (46)

16 (40)

15 (43)

 1

78 (55)

62 (44)

22 (55)

19 (54)

 2

9 (6)

14 (10)

2 (5)

1 (3)

Cytogenetic profile, n (%)a,b

 t(4;14)

–

–

13 (33)

15 (43)

 t(14;16)

–

–

4 (10)

5 (14)

 del17p

–

–

27 (68)

20 (57)

 ≥ 2 risk factorsd

–

–

4 (10)

4 (11)

Median (range) time from diagnosis, years

4.3 (0.7–20.7)

3.6 (0.6–18.6)

3.3 (1.0–10.5)

3.7 (1.0–14.8)

Prior lines of therapy, n (%)

 1

70 (50)

67 (48)

21 (53)

12 (34)

 2

32 (23)

40 (29)

11 (28)

15 (43)

 3

25 (18)

16 (11)

5 (13)

6 (17)

 > 3

14 (10)

17 (12)

3 (8)

2 (6)

 Median (range)

2 (1–9)

2 (1–10)

1 (1–6)

2 (1–4)

Prior ASCT, n (%)

90 (64)

79 (56)

27 (68)

21 (60)

Prior PI, n (%)

101 (72)

94 (67)

27 (68)

28 (80)

 Bortezomib

98 (70)

89 (64)

25 (63)

26 (74)

Prior IMiD, n (%)

104 (74)

110 (79)

28 (70)

29 (83)

 Lenalidomide

52 (37)

66 (47)

15 (38)

17 (49)

Prior PI + IMiD, n (%)

73 (52)

67 (48)

15 (38)

22 (63)

Refractory to PI only, n (%)

1 (1)

2 (1)

2 (5)

1 (3)

Refractory to IMiD only, n (%)

41 (29)

51 (36)

12 (30)

11 (31)

Refractory to PI and IMiD, n (%)

6 (4)

2 (1)

0

4 (11)

Refractory to last line of therapy, n (%)

40 (28)

48 (34)

11 (28)

14 (40)

  1. D-Vd daratumumab/bortezomib/dexamethasone, Vd bortezomib/dexamethasone, ISS International Staging System, ECOG Eastern Cooperative Oncology Group, ASCT autologous stem cell transplantation, PI proteasome inhibitor, IMiD immunomodulatory drug, FISH fluorescence in situ hybridization
  2. Note: percentages may not equal 100% due to rounding
  3. aBased on FISH/karyotype testing
  4. bPatients with high cytogenetic risk had a t(4;14), t(14;16), or del17p abnormality
  5. cISS stage is derived based on the combination of serum β2-microglobulin and albumin
  6. dPatients with ≥ 2 of the t(4;14), t(14;16), or del17p risk factors
Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us